FDA Requests the Withdrawal of the Weight-loss Drug Lorcaserin from the Market – Potential Risk of Cancer Outweighs the Benefits
16 Feb, 2020 | 21:33h | UTCSource: Lorcaserin (Belviq ) Withdrawn From US Market Due to Cancer Risk – Medscape (free registration required)
Related: FDA Safety Communication: Possible Increased Risk of Cancer with Weight-loss Medicine Lorcaserin (free)